RxDoctor Payments Data

Maurice Leonard, MD

Gastroenterology · Lumberton, NJNPI 1750334538

Payments from drug & device makers

$1,661in general payments, 2019–2025

Across 96 payments — averaging $17.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$375
  • Johnson & Johnson$290
  • Cumberland Pharmaceuticals, Inc.$205
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$156
  • Phathom Pharmaceuticals, Inc.$92
  • Takeda Pharmaceuticals U.S.A., Inc.$90
  • plus $452 from 14 others

What the payments were for

  • Food & beverage$1,661100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,661 in reported general payments places this provider in the 40th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$128,081
Medicare patients
580
Services billed
945

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab30$265,828
CreonLipase/Protease/Amylase71$154,093
XifaxanRifaximin40$120,566
LinzessLinaclotide62$65,944
Dexlansoprazole DrDexlansoprazole108$42,832
Mesalamine31$15,296
Colestipol Hcl150$14,896
MotegrityPrucalopride Succinate11$11,413
VoqueznaVonoprazan Fumarate11$8,148
Pantoprazole Sodium539$7,997
Famotidine385$5,151
Sucralfate56$4,797
Lubiprostone27$4,461
Lansoprazole67$3,898
Omeprazole156$2,609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$375$220,037133 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$156$120,56640 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$90$11,41311 claims
Phathom Pharmaceuticals, Inc.Voquezna$92$8,14811 claims
SandozLansoprazole$18$3,89867 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Lumberton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →